Keep your finger on the pulse of breakthroughs
Our team and providers are operating at the forefront of regenerative research, clinical practice, and care.
Search our databaseOther news
Do MSCs act exclusively on the immune system in neural injury?
Do MSCs act exclusively on the immune system in neural injury. An interesting study came to my attention recently.
Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study
This study provides strong evidence that autologous hematopoietic stem cell transplantation offers superior long-term clinical outcomes compared to two of the most effective current disease-modifying therapies for relapsing multiple sclerosis, particularly in terms of preventing relapses and maintaining sustained clinical benefit over a 5-year follow-up period.
Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial
This phase II randomized trial demonstrates that autologous hematopoietic stem cell transplantation (AHSCT) is significantly more effective than mitoxantrone at reducing MRI-detected disease activity in patients with aggressive multiple sclerosis. Results showed a 79% reduction in new T2 lesions and a significant decrease in relapse rates, supporting the need for larger phase III clinical trials.
